Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$0.90 USD
+0.02 (2.28%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.90 0.00 (-0.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Cytosorbents Corporation [CTSO]
Reports for Purchase
Showing records 81 - 100 ( 183 total )
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
CytoSorbents reported 2Q19 numbers with another strong quarter of growth,
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Bouncing Back With a Strong Q2; Multiple Catalysts in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cytosorbents Corporation
Industry: Medical - Products
A New Paradigm in Blood Purification - Sepsis
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Expect Return to Double-Digit Growth in Q2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
New Direct Sales Territories to Drive Growth; Clinical Studies on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Continued Focus on Revenue Growth in 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Lower Revenue Due to Seasonality; Expect Bounce Back in 4Q; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Revenue Growth and Margin Expansion Highlight a Strong 2Q18; Higher $15 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cytosorbents Corporation
Industry: Medical - Products
REFRESH 2 On Track; HemoDefend Could Unlock New Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S